Articles - FCS Hematology Oncology Review

Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

March 1, 2026

This is a strong adjuvant signal in resected stage III dMMR colon cancer, adding atezolizumab to mFOLFOX6 cut the risk of recurrence or death in half and improved 3-year DFS from 76% to 86%. OS hasn’t separated yet, but that may be confounded by immunotherapy at relapse. Toxicity was higher, as expected, with more grade 3–4 events and immune-related adverse events (AE)s, but overall manageable. This feels practice changing for stage III dMMR disease.

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

March 1, 2026

Setidegrasib represents a meaningful advance in targeting KRAS G12D–mutant tumors, demonstrating a 36% response rate with median PFS exceeding 8 months in heavily pretreated NSCLC, and a 24% response rate with ~10 month median overall survival (OS) in third line pancreatic cancer, both notable signals in populations lacking approved targeted therapies.

Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

February 1, 2026

Use of recombinant factor VII slowed the progression of hematomas but did not improve cognitive function and increased the risk of thrombosis.

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal

February 1, 2026

DON’T… more toxic, no benefit.

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

February 1, 2026

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial

February 1, 2026

With the addition of intrahepatic chemotherapy, median overall survival was 22.3 months. One year overall survival reached 80.0%, exceeding the historical control rate of 47%, while three year overall survival was 31.5%. For patients who can tolerate this approach, it appears to be a reasonable and potentially worthwhile option.

Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Survivors of Cancer: A Randomized Clinical Trial

February 1, 2026

Music therapy is noninferior to CBT for anxiety in survivors of cancer. Music therapy was found to be noninferior to cognitive behavioral therapy for anxiety among cancer survivors. Both telehealth interventions produced clinically meaningful and durable improvements in anxiety. Should we hire musicians?

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

February 1, 2026

A B7 homolog 3–directed antibody-drug conjugate, demonstrated an overall response rate of 48.2%, with a median duration of response of 5.3 months, and a median progression-free survival of 4.9 months. The 9-month overall survival estimate was 59.1%. This represents another ADC with promising activity, although interstitial lung disease remains a concern, occurring in approximately 12% of patients.

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

February 1, 2026

A promising anti TP53 agent demonstrated an overall response rate of 20%, increasing to 30% in patients with KRAS wild type disease. Nausea and vomiting were the most commonly reported adverse events. While early, this agent may warrant continued attention as additional data emerge.

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

February 1, 2026

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Article Search

Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial

Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Survivors of Cancer: A Randomized Clinical Trial

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site